Acute Lymphoid Leukemia
Combinatorial gene therapy offers antitumor protection to leukemia models
Published in Cancer Gene Therapy Week, June 14th, 2004
"We report in a murine model of acute lymphoid leukemia L1210 the potent antitumor efficiency of a combinatorial delivery of pro-interleukin (IL)-18 gene modified L1210 (Lp18) and IL-1beta converting enzyme (ICE) gene modified L1210 (LpICE). Live leukemia cells Lp18 or Lp18 plus LpICE showed apparently reduced leukemo-genicity with a survival rate of 40% or 50% at 50 days after intraperitoneal (i.p) inoculation of a lethal dose of cells, respectively." researchers in the Peoples Republic of China report.
"Combination of Lp18 and LpICE was capable of inhibiting accumulation of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Gene Therapy Week
More Articles from Cancer Gene Therapy Week
- Drug Development
Antisense oligonucleotide LErafAON enhances the work of standard chemotherapy - Blood Vessels
NCI awards funding for tumor-targeted siRNA therapeutic - Brain Cancer
Cationic lipid-DNA complexes slow glioblastoma growth in murine models - Cancer Therapy
Company presents update on TNFerade at Digestive Disease Week - Cervical Cancer
Recombinant adenovirus p53 effects cancer cell apoptosis - Gene Mutation
Mutations in gene encoding filamin B disrupt vertebral segmentation - More from this issue of Cancer Gene Therapy Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
